ARTICLE | Distillery Therapeutics
Biomarkers
October 27, 2016 7:00 AM UTC
A panel of five microRNAs could be used for the differential diagnosis of subtypes of aggressive prostate cancer and to predict the risk of disease progression. Exon sequencing of serum samples from e...